KLK4 and ischemia: Intriguingly, MSCs genetically modified with the kallikrein gene were more effective in reducing inflammatory cell infiltration, decreasing reactive oxygen species formation, and mitigating ischemia-induced renal injury than unmodified MSCs due to the combination of MSC-mediated paracrine effects and the pleiotropic properties of kallikrein [49].